# Tezepelumab-Ekko (Tezspire)

Source: https://ourhealthnetwork.com/drugs/tezepelumab-ekko
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Tezepelumab-Ekko?

Tezepelumab-Ekko (brand name: Tezspire) is a thymic stromal lymphopoietin blocker. It is prescribed to treat asthma. Across the United States, 646 doctors prescribe Tezepelumab-Ekko to approximately 202 Medicare patients.

## Brand names

Tezspire

## Indications

Tezepelumab-Ekko is primarily prescribed for the treatment of asthma.

## Conditions treated

- [Asthma](https://ourhealthnetwork.com/conditions/asthma)

## Mechanism of action

Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades.

## Drug classification

- Established Pharmacologic Class: Thymic Stromal Lymphopoietin Blocker [EPC]
- Mechanism of Action class: Thymic Stromal Lymphopoietin Blockers [MoA]
- Route of administration: SUBCUTANEOUS

## Common side effects

arthralgia, back pain, • asthma: pharyngitis

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)